272 related articles for article (PubMed ID: 23807645)
1. Diabetic nephropathy: new approaches for improving glycemic control and reducing risk.
Schernthaner G; Schernthaner GH
J Nephrol; 2013; 26(6):975-85. PubMed ID: 23807645
[TBL] [Abstract][Full Text] [Related]
2. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
3. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Bourdel-Marchasson I; Schweizer A; Dejager S
Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
5. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
6. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.
Kanasaki K
Clin Sci (Lond); 2018 Feb; 132(4):489-507. PubMed ID: 29491123
[TBL] [Abstract][Full Text] [Related]
7. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin as add-on therapy to insulin for patients with type 2 diabetes.
von Websky K; Reichetzeder C; Hocher B
Vasc Health Risk Manag; 2013; 9():681-94. PubMed ID: 24204157
[TBL] [Abstract][Full Text] [Related]
9. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment.
Mikov M; Pavlović N; Stanimirov B; Đanić M; Goločorbin-Kon S; Stankov K; Al-Salami H
Eur J Drug Metab Pharmacokinet; 2020 Feb; 45(1):1-14. PubMed ID: 31385198
[TBL] [Abstract][Full Text] [Related]
10. The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Muskiet MH; Smits MM; Morsink LM; Diamant M
Nat Rev Nephrol; 2014 Feb; 10(2):88-103. PubMed ID: 24375052
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin as add-on therapy for type 2 diabetes - an overview.
Brown DX; Choudhury M; Evans M
Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes.
Forst T; Pfützner A
Expert Opin Pharmacother; 2012 Jan; 13(1):101-10. PubMed ID: 22149370
[TBL] [Abstract][Full Text] [Related]
13. Linagliptin for the treatment of type 2 diabetes mellitus: a drug safety evaluation.
Barnett AH
Expert Opin Drug Saf; 2015 Jan; 14(1):149-59. PubMed ID: 25351273
[TBL] [Abstract][Full Text] [Related]
14. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
15. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
16. [New oral hypoglycemic drugs in diabetic kidney disease].
Dylewska M; Graczyk M
Wiad Lek; 2017; 70(6 pt 2):1193-1196. PubMed ID: 29533912
[TBL] [Abstract][Full Text] [Related]
17. The effects of glucose-lowering therapies on diabetic kidney disease.
Agrawal V; Giri C; Solomon RJ
Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective Effects of Incretin-Based Therapy in Diabetes Mellitus.
Yaribeygi H; Atkin SL; Montecucco F; Jamialahmadi T; Sahebkar A
Biomed Res Int; 2021; 2021():8163153. PubMed ID: 34471642
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
20. Linagliptin use in older individuals with type 2 diabetes.
Pratley RE
Clin Interv Aging; 2014; 9():1109-14. PubMed ID: 25083132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]